Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 73 articles:
HTML format
Text format



Single Articles


    November 2018
  1. TIAN J, Raffa FA, Dai M, Moamer A, et al
    Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
    Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0287.
    PubMed     Text format     Abstract available


  2. GIANNAKEAS V, Cadarette SM, Ban JK, Lipscombe L, et al
    Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0225.
    PubMed     Text format     Abstract available


  3. SNELL CE, Gough M, Liu C, Middleton K, et al
    Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-alpha and progesterone receptor-b.
    Br J Cancer. 2018 Nov 9. pii: 10.1038/s41416-018-0331.
    PubMed     Text format     Abstract available


    October 2018
  4. MCGREGOR RJ, Chau YY, Kendall TJ, Artibani M, et al
    WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer.
    Br J Cancer. 2018 Oct 30. pii: 10.1038/s41416-018-0317.
    PubMed     Text format     Abstract available


  5. MUNSTER P, Krop IE, LoRusso P, Ma C, et al
    Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
    Br J Cancer. 2018 Oct 26. pii: 10.1038/s41416-018-0235.
    PubMed     Text format     Abstract available


  6. TAMBOUR M, Holt M, Speyer A, Christensen R, et al
    Manual lymphatic drainage adds no further volume reduction to Complete Decongestive Therapy on breast cancer-related lymphoedema: a multicentre, randomised, single-blind trial.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0306.
    PubMed     Text format     Abstract available


  7. BERTUCCI F, Finetti P, Simeone I, Hendrickx W, et al
    The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0309.
    PubMed     Text format     Abstract available


  8. LANGBALLE R, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
    Statin use and risk of contralateral breast cancer: a nationwide cohort study.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0252.
    PubMed     Text format     Abstract available


  9. WALASZEK K, Lower EE, Ziolkowski P, Weber GF, et al
    Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0228.
    PubMed     Text format     Abstract available


  10. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0177.
    PubMed     Text format    


  11. SCIMECA M, Urbano N, Bonfiglio R, Schillaci O, et al
    Breast osteoblast-like cells: a new biomarker for the management of breast cancer.
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0255.
    PubMed     Text format     Abstract available


  12. MEURS CJC, van Rosmalen J, Menke-Pluijmers MBE, Ter Braak BPM, et al
    A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers.
    Br J Cancer. 2018 Oct 17. pii: 10.1038/s41416-018-0276.
    PubMed     Text format     Abstract available


  13. CHAKRABORTY S, Jiang C, Gau D, Oddo M, et al
    Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0284.
    PubMed     Text format     Abstract available


  14. O'CARRIGAN B, Lim JSJ, Jalil A, Harris SJ, et al
    Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0290.
    PubMed     Text format     Abstract available


  15. BAJOR M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, et al
    Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0263.
    PubMed     Text format     Abstract available


  16. KRUGER DT, Beelen KJ, Opdam M, Sanders J, et al
    Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0221.
    PubMed     Text format     Abstract available


  17. STEVENS RG
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 Oct 3. pii: 10.1038/s41416-018-0058.
    PubMed     Text format    


  18. BECKWITT CH, Clark AM, Ma B, Whaley D, et al
    Statins attenuate outgrowth of breast cancer metastases.
    Br J Cancer. 2018;119:1094-1105.
    PubMed     Text format     Abstract available


  19. MADSSEN TS, Thune I, Flote VG, Lundgren S, et al
    Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment.
    Br J Cancer. 2018;119:1144-1154.
    PubMed     Text format     Abstract available


    September 2018
  20. GRAY E, Marti J, Brewster DH, Wyatt JC, et al
    Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data.
    Br J Cancer. 2018 Sep 17. pii: 10.1038/s41416-018-0256.
    PubMed     Text format     Abstract available


    August 2018
  21. BOEKEL NB, Jacobse JN, Schaapveld M, Hooning MJ, et al
    Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.
    Br J Cancer. 2018 Aug 1. pii: 10.1038/s41416-018-0159.
    PubMed     Text format     Abstract available


    July 2018
  22. SAHA A, Harowicz MR, Grimm LJ, Kim CE, et al
    A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0185.
    PubMed     Text format     Abstract available


  23. TAKADA K, Kashiwagi S, Goto W, Asano Y, et al
    Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0197.
    PubMed     Text format     Abstract available


  24. LAMMERS PE, Dank M, Masetti R, Abbas R, et al
    Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.
    Br J Cancer. 2018 Jul 13. pii: 10.1038/s41416-018-0147.
    PubMed     Text format     Abstract available


  25. STERLE HA, Nicoud MB, Massari NA, Taquez Delgado MA, et al
    Immunomodulatory role of histamine H4 receptor in breast cancer.
    Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0173.
    PubMed     Text format     Abstract available


    June 2018
  26. LO LL, Milne RL, Liao Y, Cuzick J, et al
    Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.
    Br J Cancer. 2018 Jun 21. pii: 10.1038/s41416-018-0120.
    PubMed     Text format     Abstract available


  27. CHERIYATH V, Kaur J, Davenport A, Khalel A, et al
    G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0137.
    PubMed     Text format     Abstract available


  28. GUIU S, Mollevi C, Charon-Barra C, Boissiere F, et al
    Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
    Br J Cancer. 2018 Jun 8. pii: 10.1038/s41416-018-0142.
    PubMed     Text format     Abstract available


  29. DERKS MGM, Bastiaannet E, Kiderlen M, Hilling DE, et al
    Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group.
    Br J Cancer. 2018 Jun 7. pii: 10.1038/s41416-018-0090.
    PubMed     Text format     Abstract available


  30. ROHAN TE, Miller CA, Li T, Wang Y, et al
    Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0089.
    PubMed     Text format     Abstract available


  31. TUNG NM, Garber JE
    BRCA1/2 testing: therapeutic implications for breast cancer management.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
    PubMed     Text format     Abstract available


  32. HALKETT G, O'Connor M, Jefford M, Aranda S, et al
    RT Prepare: a radiation therapist-delivered intervention reduces psychological distress in women with breast cancer referred for radiotherapy.
    Br J Cancer. 2018 Jun 1. pii: 10.1038/s41416-018-0112.
    PubMed     Text format     Abstract available


    May 2018
  33. WEIN L, Luen SJ, Savas P, Salgado R, et al
    Checkpoint blockade in the treatment of breast cancer: current status and future directions.
    Br J Cancer. 2018 May 29. pii: 10.1038/s41416-018-0126.
    PubMed     Text format     Abstract available


  34. GULLO G, Walsh N, Fennelly D, Bose R, et al
    Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
    Br J Cancer. 2018 May 18. pii: 10.1038/s41416-018-0114.
    PubMed     Text format     Abstract available


  35. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0092.
    PubMed     Text format    


  36. MORTAZAVI SMJ
    Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study'.
    Br J Cancer. 2018 May 17. pii: 10.1038/s41416-018-0060.
    PubMed     Text format    


  37. FRENCH DP, Southworth J, Howell A, Harvie M, et al
    Psychological impact of providing women with personalised 10-year breast cancer risk estimates.
    Br J Cancer. 2018 May 8. pii: 10.1038/s41416-018-0069.
    PubMed     Text format     Abstract available


  38. CHEN S, Wang H, Li Z, You J, et al
    Interaction of WBP2 with ERalpha increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0119.
    PubMed     Text format     Abstract available


  39. DERKS-SMEETS IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al
    Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0139.
    PubMed     Text format     Abstract available


    April 2018
  40. BHARTI R, Dey G, Das AK, Mandal M, et al
    Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0078.
    PubMed     Text format     Abstract available


  41. ORECCHIONI S, Talarico G, Labanca V, Calleri A, et al
    Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0076.
    PubMed     Text format     Abstract available


  42. LIIKANEN JS, Leidenius MH, Joensuu H, Vironen JH, et al
    Prognostic value of isolated tumour cells in sentinel lymph nodes in early-stage breast cancer: a prospective study.
    Br J Cancer. 2018 Apr 24. pii: 10.1038/s41416-018-0052.
    PubMed     Text format     Abstract available


    March 2018
  43. JOSEPH C, Macnamara O, Craze M, Russell R, et al
    Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
    Br J Cancer. 2018 Mar 28. pii: 10.1038/s41416-018-0041.
    PubMed     Text format     Abstract available


  44. QUIROS-GONZALEZ I, Tomaszewski MR, Aitken SJ, Ansel-Bollepalli L, et al
    Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry.
    Br J Cancer. 2018 Mar 26. pii: 10.1038/s41416-018-0033.
    PubMed     Text format     Abstract available


  45. MCNAMARA KM, Guestini F, Sauer T, Touma J, et al
    In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics.
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0034.
    PubMed     Text format     Abstract available


  46. GYORFFY B, Pongor L, Bottai G, Li X, et al
    An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0030.
    PubMed     Text format     Abstract available


  47. EL ANSARI R, Craze ML, Diez-Rodriguez M, Nolan CC, et al
    The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.
    Br J Cancer. 2018 Mar 16. pii: 10.1038/s41416-018-0038.
    PubMed     Text format     Abstract available


  48. SAUERBREI W, Haeussler T
    Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses'.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0023.
    PubMed     Text format    


  49. POUJADE FA, Mannion A, Brittain N, Theodosi A, et al
    WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0056.
    PubMed     Text format     Abstract available


  50. PAPADAKIS ES, Reeves T, Robson NH, Maishman T, et al
    Reply to 'Comment on 'BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses''.
    Br J Cancer. 2018 Mar 15. pii: 10.1038/s41416-018-0032.
    PubMed     Text format    


    February 2018
  51. REMSIK J, Fedr R, Navratil J, Bino L, et al
    Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer.
    Br J Cancer. 2018 Feb 20. pii: bjc2017497. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  52. DOSS M
    Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure'.
    Br J Cancer. 2018 Feb 13. pii: bjc2017481. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  53. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    Reply to 'Comment on '30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure''.
    Br J Cancer. 2018 Feb 13. pii: bjc2017490. doi: 10.1038/bjc.2017.
    PubMed     Text format    


    January 2018
  54. LEGLER K, Rosprim R, Karius T, Eylmann K, et al
    Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017472. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  55. FOUKAKIS T, Lovrot J, Matikas A, Zerdes I, et al
    Immune gene expression and response to chemotherapy in advanced breast cancer.
    Br J Cancer. 2018 Jan 25. pii: bjc2017446. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  56. PLYM A, Bower H, Fredriksson I, Holmberg L, et al
    Loss in working years after a breast cancer diagnosis.
    Br J Cancer. 2018 Jan 23. pii: bjc2017456. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  57. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
    Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
    Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  58. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.
    Br J Cancer. 2018 Jan 23. pii: bjc2017359. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  59. TRUDEL-FITZGERALD C, Zhou ES, Poole EM, Zhang X, et al
    Sleep and survival among women with breast cancer: 30 years of follow-up within the Nurses' Health Study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017437. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    December 2017
  60. REDDY SM, Barcenas CH, Sinha AK, Hsu L, et al
    Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
    Br J Cancer. 2017 Dec 12. pii: bjc2017379. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    November 2017
  61. CRAZE ML, Cheung H, Jewa N, Coimbra NDM, et al
    MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
    Br J Cancer. 2017 Nov 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  62. NANDY SB, Orozco A, Lopez-Valdez R, Roberts R, et al
    Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis.
    Br J Cancer. 2017;117:1665-1675.
    PubMed     Text format     Abstract available


  63. DANIELS B, Kiely BE, Houssami N, Lord SJ, et al
    Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014).
    Br J Cancer. 2017 Nov 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    October 2017
  64. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    PubMed     Text format     Abstract available


  65. HSIEH WH, Lin IF, Ho JC, Chang PW, et al
    30 years follow-up and increased risks of breast cancer and leukaemia after long-term low-dose-rate radiation exposure.
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  66. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Text format     Abstract available


  67. PONZETTI M, Capulli M, Angelucci A, Ventura L, et al
    Non-conventional role of haemoglobin beta in breast malignancy.
    Br J Cancer. 2017;117:994-1006.
    PubMed     Text format     Abstract available


  68. MORRELL S, Roder D, Taylor R
    Reply to 'Comment on 'Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study''.
    Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  69. GREGOIRE C, Bragard I, Jerusalem G, Etienne AM, et al
    Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  70. YE ZJ, Qiu HZ, Liang MZ, Liu ML, et al
    Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial.
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  71. OSAKO T, Iwase T, Ushijima M, Yonekura R, et al
    A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  72. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Text format     Abstract available


    August 2017
  73. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: